

March 1, 2018

# NanoVibronix Announces Positive Response to UroShield(TM) Presentation at the Infection Prevention and Control 2018 London Conference

ELMSFORD, NY -- (Marketwired) -- 03/01/18 -- **NanoVibronix, Inc.**, (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology today announced that Dr. Harold Jacob, M.D., Chief Medical Officer of NanoVibronix, led a workshop at the Infection Prevention and Control 2018 London Conference entitled "Low Frequency/Low Intensity Ultrasound -- a Breakthrough in Treating Catheter-Associated Urinary Tract Infection (CAUTI)."

Dr. Jacob presented clinical data regarding the Company's UroShield™ device, as well as recent evidence demonstrating the device reduces CAUTIs. In addition, Dr. Jacob discussed how the device has the potential to help the UK National Health Service (NHS) achieve its objectives such as reducing the use of antibiotics, lowering infection rates, decreasing hospital admissions and improving patient safety. The workshop was hosted by the Company's newly announced UK distributor, IMS Ultrasound, a wholly owned subsidiary of Ideal Medical Solutions Limited.

UroShield™ is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of CAUTI. UroShield is also intended to decrease pain and discomfort associated with urinary catheter use.

Brian Murphy, Chief Executive Officer, of NanoVibronix, commented, "We are extremely pleased with the favorable response we received at the Infection Prevention and Control 2018 London Conference. Conference attendees included many of the top key opinion leaders (KOLs) across Europe in the field of infectious diseases. CAUTI is the second most common cause of hospital-acquired infection with an estimated 15-25% of patients admitted to NHS hospitals in the UK requiring catheterization. Tragically, CAUTI is associated with a significant increase in patient mortality. UroShield™ is a highly effective means of lowering infection rates and improving patient outcomes."

Mr. Murphy continued, "We are very pleased with the progress that IMS Ultrasound, our UK distributor, has made in the short time since we announced the partnership. This workshop presentation is a good illustration of the positive response to UroShield™, especially among the clinicians in the fields of urology and infectious disease. The fact that our device effectively reduces bacterial colonization and biofilm that is common with indwelling catheters, will ultimately reduce healthcare costs and save lives."

Dr. Jacob is board certified in Internal Medicine and Gastroenterology and a member of

the American College of Medicine and American Gastroenterological Association (AGA) and a Fellow of the American College of Gastroenterology (ACG). He founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology. Dr. Jacob has served as an attending physician at Hadassah University Medical Center and was the Director of the Gastrointestinal Endoscopy Unit. He served as Co-Chief of Gastroenterology at St. John's Episcopal Hospital in New York, Clinical Assistant Professor of Medicine at SUNY Brooklyn and Chief of Gastro at South Nassau Communities Hospital, Oceanside, New York. He is also part time attending in Gastroenterology at Bikur Cholim Hospital in Israel. He has patented and licensed a number of medical devices in daily hospital use today.

***About NanoVibronix***

NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, NY with research and development in Neshar, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered at home, without the assistance of medical professionals. The company's products include PainShield® UroShield™ NG-Shield™ and WoundShield™. Additional information about the company is available at: [www.nanovibronix.com](http://www.nanovibronix.com).

Contact:

Crescendo Communications

[naov@crescendo-ir.com](mailto:naov@crescendo-ir.com)

212-671-1021

Source: NanoVibronix, Inc.